|Home | About | Journals | Submit | Contact Us | Français|
Certain mutations within the protective antigen (PA) moiety of anthrax toxin endow the protein with a dominant-negative (DN) phenotype, converting it into a potent antitoxin. Proteolytically activated PA oligomerizes to form ring-shaped heptameric complexes that insert into the membrane of an acidic intracellular compartment and promote translocation of bound edema factor and/or lethal factor to the cytosol. DN forms of PA co-oligomerize with the wild-type protein and block the translocation process. We prepared and characterized 4 DN forms: a single, a double, a triple, and a quadruple mutant. The mutants were made by site-directed mutation of the cloned form of PA in Escherichia coli and tested by various assays conducted on CHO cells or in solution. All 4 mutant PAs were competent for heptamerization and ligand binding but were defective in the pH-dependent functions: pore formation, ability to convert to the SDS-resistant heptamer, and ability to translocate bound ligand. The single mutant (F427K) showed less attenuation than the others in the pH-dependent functions and lower DN activity in a CHO cell assay. The quadruple (K397D + D425K + F427A + 2β2-2β3) deletion showed the most potent DN activity at low concentrations but also gave indications of low stability in a urea-mediated unfolding assay. The double mutant (K397D + D425K) and the triple (K397D + D425K + F427A) showed strong DN activity and slight reduction in stability relative to the wild-type protein. The properties of the double and the triple mutants make these forms worthy of testing in vivo as a new type of antitoxic agent for treatment of anthrax.
The major symptoms of anthrax are believed to result from the effects of a tripartite toxin secreted by the anthrax bacillus, Bacillus anthracis. Anthrax toxin consists of 3 large proteins that assemble at the surface of receptor-bearing mammalian cells to form toxic, noncovalent complexes (1,2). Two of the proteins, lethal factor (LF) and edema factor (EF), are enzymes that covalently modify substrates within the cytosolic compartment. The 3rd, protective antigen (PA), serves to bind LF and EF to the cell and mediate their entry into the cytosol.
Our current working model of assembly and entry of the toxic complexes is as follows: Assembly begins when PA binds to a cell-surface receptor and is cleaved into 2 fragments by a member of the furin family of cell-associated proteases (3,4). Trypsin cleaves PA preferentially at the furin site and may be used to activate the protein in solution. The smaller, N-terminal fragment (PA20, 20 kDa) dissociates into the medium, leaving the complementary fragment (PA63, 63 kDa) bound to the receptor. Removal of PA20 relieves a steric barrier to oligomerization of PA63 and to its binding of EF and LF (5). PA63 self-associates to form 7-membered, ring-shaped oligomers (6), and these heptamers bind EF and LF competitively. The resulting hetero-oligomers, containing up to 3 molecules of EF and/or LF per PA63 heptamer, are endocytosed and trafficked to an acidic compartment within the cell (7). There, the low pH promotes a conformational change in the PA63 heptamer that allows it to insert into the membrane and form a pore (8). Concurrently EF and LF translocate across the membrane to the cytosol. EF catalyzes conversion of ATP to cAMP (9), and LF proteolytically attacks certain MAP kinase kinases and perhaps other cytosolic proteins (10,11).
Clues to the conformational change involved in conversion of the preinsertion form of the PA63 heptamer (termed the prepore) to the pore form came from the crystallographic structures of the prepore and of intact PA (5). A disordered loop (2β2-2β3) of the pore-forming domain (domain 2) showed sequence characteristics consistent with the formation of a transmembrane, amphipathic β-barrel (similar to that of the Staphylococcal α-toxin). Evidence to support this model came from electrophysiological measurements on PA mutants containing Cys-substitutions within the 2β2-2β3 loop (12). The loop in the prepore is located in the midsection of domain 2 as part of a Greek key motif. It was proposed that for the transmembrane β-barrel to form, the 2 β strands flanking the loop must be stripped out from the body of the domain, allowing the loop to relocate to the base of the structure. Clearly this implies a major conformational change in the domain. Consistent with this notion, the prepore becomes resistant to dissociation by sodium dodecyl sulfate (SDS) as it converts to the pore conformation (6).
Recently we reported that mutation of 3 residues in 2 loops on the opposite (luminal) face of domain 2 blocked the ability of PA to mediate translocation of bound ligands (13). Also, deletion of the 2β2-2β3 loop blocked both pore formation and translocation, as predicted by the β-barrel model (14). Later experiments showed that some of these mutations, or combinations of them, endowed PA with a dominant-negative (DN) phenotype (15). When mixed with wild-type PA, the DN-PAs strongly inhibited translocation both in vitro and in vivo. Among the mutants tested, a double, K397D + D425K, was found have the most potent dominant-negative activity. Also, a mutant PA in which residues of the 2β2-2β3 loop were replaced with a corresponding region of the PA homolog from iota toxin of Clostridium perfringens was reported to have similar properties (16). We believe the various dominant-negative mutations in some way block the conformational change in domain 2 required for conversion of the prepore to the pore.
These findings raised the possibility that DN-PAs might represent a novel approach to therapy of anthrax. In the current study we have examined the characteristics of a selected set of DN-PAs that are candidates for further testing in animals as novel antitoxins. The double, K397D + D425K, mutant was used as the primary template to analyze the effects of additional mutations.
Chinese Hamster Ovary-K1 (CHO-K1) cells were obtained from the American Type Culture Collection. Cells were grown in Ham’s F-12 medium supplemented with 10% calf serum, 2 mM glutamine, 500 units/mL penicillin, and 500 units/mL streptomycin sulfate and maintained at 5% CO2 in a humidified atmosphere. All supplies for the cell culture were from Invitrogen Technologies, unless noted otherwise. All chemicals were obtained from Sigma Chemical Co, unless specified.
Mutations were constructed following the QuickChange (Strata-gene Inc) method of site-directed mutagenesis. Mutations were cloned into the expression vector pET22b(+), transformed into E. coli (XL-1 Blue) by electroporation. Mutagenesis was confirmed by sequencing. Proteins were expressed in E. coli (BL21 DE3) by induction with 1 mM IPTG at 30 °C for 3 h. Cells from a 2.5-L culture were harvested by centrifugation at 8000 × g, resuspended in 500 mL 20 mM Tris, pH 8.0, 20% sucrose, and 1mM EDTA, and stirred at 4°C for 15 min. After recentrifugation at 8000 × g, cells were resuspended in 500 mL ice-cold 5 mM MgSO4 and stirred at 4 °C for 15 min. The periplasmic shock extract was obtained by decanting after centrifugation at 10000 × g at 4 °C for 15 min. The periplasmic shock extract then was loaded onto a Q-Sepharose column. After equilibration with Buffer A (20 mM Tris, pH 8.0), proteins were eluted with a linear gradient of 0% to 35% Buffer B (20 mM Tris pH 8.0, 1 M NaCl). The collected fractions were monitored by 11.25% SDS-PAGE, and those containing PA at more than 90% purity were pooled and stored at −80 °C. Protein concentration was determined by the Bradford assay (Bio-Rad Laboratories).
Preseeded CHO-K1 (2.5 × 105/mL) cells were chilled on ice for 15 min. Then 1 μg per well trypsin-nicked PA in 250 μL ice-cold F-12-HEPES, pH 8.0, was added. After incubation on ice for 1 h, 250 μl [35S]-LFn, produced in an in vitro transcription-translation system using TNT Coupled Reticulocyte Lysate system (Promega Inc), dissolved in ice-cold F-12, and buffered with 20 mM HEPES, pH 8.0, was added. Then the cells were incubated on ice for 1 h. The unbound [35S]-LFn was removed by aspiration, and [35S]-LFn translocation was triggered by treatment of 250 μl translocation buffer (140 mM NaCl, 20 mM 2-[N-morpholino] ethanesulfonic acid (MES) 5 mM gluconic acid, pH 4.8) at 37 °C for 1 min. Pronase (1 mg/well in F-12-HEPES, pH 8.0) was added into some wells to remove LFn bound on cell surface after translocation. Cells treated with or without protease were lysed in 250 μL lysis buffer (20 mM sodium phosphate, pH 7.4, 10 mM EDTA, 1% Triton X-100). Samples were counted in a scintillation counter. The efficiency of translocation was calculated as dpm protected from protease/dpm total [35S]LFn bound on cell surface.
CHO-K1 cells were seeded at a density of 1.5 ×105/mL in 24 well plates and incubated at 37 °C overnight. The medium was removed and replaced with fresh F-12 medium containing 1 μCi/mL 86Rb (NEN Inc) and incubated overnight. Cells were chilled on ice for 15 min and washed with chilled phosphate-buffered saline (PBS) followed by addition of 1 μg trypsin nicked PA in 250 μL F-12-HEPES buffer, pH 8.0. After incubation on ice for 1 h, cells were washed with ice-cold PBS, followed by addition of pH 4.8 or pH 8.0 buffer (140 mM NaCl, 20 mM MES, 5 mM gluconic acid, pH 4.8 or pH 8.0). After 15 min incubation, supernatant containing released 86Rb was collected and counted in a gamma-counter.
Mutant or wild type (WT)-PA (6 μg protein) were treated with 6 ng trypsin at room temperature for 30 min followed by 60 ng trypsin inhibitor at room temperature for 15 min. Trypsin-nicked PA was incubated with an equimolar amount of LFn at room temperature for 2 h. After incubation, samples were loaded onto 4% to 20% native gradient gels (BioWhittaker Molecular Applications Inc). After electrophoresis, proteins were visualized by Coomassie Brilliant Blue staining.
Trypsin-nicked PA (6 μg) was incubated with an equimolar amount of LFn at room temperature for 2 h. Formation of SDS-resistant heptamer was triggered by adding 100 mM sodium acetate pH 4.0 until the pH reached 5.0. After incubation at room temperature for 30 min, samples were dissolved in SDS-PAGE sample buffer and run on a 4% to 20% gradient SDS-PAGE (BioWhittaker Molecular Applications Inc). Proteins were visualized by Coomassie Brilliant Blue staining.
A mixture of various amounts of DN mutants with a constant amount of WT-PA (2 × 10–10 M) and LFn-DTA (1 ×10–9 M) was added into 96-well plates previously seeded with CHO-K1 cells (2.5 ×105 cells/well). DTA is the catalytic domain of diphtheria toxin. After incubation at 37 °C for 4 h, the medium containing PA and LFn-DTA was removed and replaced with leucine-free F-12 medium supplemented with 1 μCi/mL [3H]-leucine (NEN Inc). After incubation with CHO-K1 cells at 37 °C for 1 h, the efficiency of inhibiting PA-dependent cell killing was monitored by measuring the quantity of [3H]-leucine incorporated.
PA (50 μg in 1 mL) was incubated with various concentrations of urea at room temperature overnight. The Trp emission spectrum was then recorded with excitation wavelength of 295 nm in ISS K2 spectrofluorometer (ISS, Inc). Stability of protein structure was monitored by red shift of λmax and the attenuation of emission.
In our initial report, a deletion mutation (Δ2β2-2β3), 2 individual point mutations (D425K and F427A), and a double mutation (K397D + D425K) were shown in a cell culture assay to confer the DN phenotype on PA (15). The K397D mutation alone did not confer this phenotype, but enhanced the DN effect of the D425K mutation. Three of the DN PAs were tested in the Fischer 344 rat model of anthrax lethal toxin action, and all were shown to be effective in rescuing the animals (15). We have now chosen 4 DN forms of PA to test further: a single mutant (F427K); a double (K397D + D425K); a triple (K397D + D425K + F427A); and a quadruple (K397D + D425K + F427A + Δ2β2-2β3). The 4 mutant proteins were expressed in E. coli, purified and tested for selected activities and stability.
We tested the ability of the 4 mutants to bind and translocate radiolabeled LFn across the plasma membrane of CHO-K1 cells in response to a low-pH pulse. LFn is the N-terminal, PA63-binding domain of LF. We bound trypsin-activated PA to CHO-K1 cells at 4 °C, and then added [35S]-LFn. Cell-bound radiolabel was quantified before and after treatment of the cells with buffer of pH 4.8. The mutant PAs bound essentially the same amount of LFn as wild-type PA. All 4 mutant proteins were severely impaired in translocation (Figure 1), and no significant differences in translocation efficiency were seen.
The ability of the mutant PAs to permeabilize the plasma membrane under acidic conditions also was tested. Cells were loaded with 86Rb, incubated with trypsin-nicked PA for 1 h on ice, washed, and then treated with buffer of pH 5 or pH 8. As shown in Figure 2, all of the mutants were severely impaired in release of 86Rb at pH 5, although the F427K mutant showed significantly greater release than the others.
The abilities of the mutant proteins to form heptameric oligomers were examined by gel electrophoresis. When trypsin-nicked PA is incubated with LFn, the ligand promotes oligomerization of the PA63 moiety, and the resulting liganded PA63 heptamer runs as a low-mobility band on polyacrylamide gels under nondenaturing conditions. As shown in Figure 3A, the 4 mutant forms of PA showed no impairment in forming these ligand complexes. Such complexes remain dissociable by SDS if the pH is maintained above approximately pH 8. If the medium is acidified however, the heptameric PA63 moiety converts to an SDS resistant form, which has been hypothesized to correspond to the pore form. As shown in Figure 3B, the double, the triple, and the quadruple mutants were unable to convert to the SDS-resistant form at pH 5.0. The F427K mutant gave a readily detectable amount of this form however, consistent with its activity in the 86Rb release assay.
To compare their potency as DN inhibitors, we tested each of the mutant proteins for ability to antagonize the inhibition of protein synthesis in CHO-K1 cells by a mixture of wild-type PA and LFn-DTA. LFn-DTA contains LFn fused to DTA, which catalyzes the ADP-ribosylation of elongation factor-2 upon entry into the cytosol. As shown in Figure 4, all 4 mutants almost completely blocked toxin action at a molar ratio ≥1 with respect to wild-type PA. The double and triple mutants were significantly more potent, and the quadruple showed the greatest activity at lower concentrations.
The current model of DN action assumes that a DN mutant must co-oligomerize with wild-type PA. This is believed to occur after binding of these forms of PA to their cell-surface receptor. Figure 5 shows that introducing a mutation that inhibits receptor binding (N682S) into the double mutant virtually ablated its DN activity, as predicted. However, introducing the oligomerization-blocking mutation, D512K, into the double did not affect DN activity. The significance of this finding is discussed below.
To test the relative stabilities of the 4 mutant PAs, we examined their unfolding as a function of urea concentration, using intrinsic tryptophan fluorescence as an index of structure perturbation. All of them showed λmax of 327 to 329 nm in the absence of urea. This value increased to values of 338 nm or greater as the urea concentration was raised to 2 M. As shown in Figure 6, the intensity of emission at the λmax declined to a constant value over this range of concentrations. With the quadruple mutant, the decline occurred at a significantly lower concentration than with the other mutants. The wild-type PA showed the highest resistance to unfolding, and the curves of the other mutants showed slight reductions in stability.
Demonstration that certain mutations within the PA moiety of anthrax toxin convert the protein into a potent inhibitor of toxin action is relevant both to the mechanism of toxin action and to development of new types of therapeutics for anthrax. The existence of such mutations strongly supports the notion that translocation of EF and LF is mediated by a multisubunit (heptameric) form of PA that forms a transmembrane pathway for EF and LF to cross to the cytosol. Introduction of a translocation-defective subunit into the heptamer—perhaps even in single copy—is able to interfere with the membrane-penetration and translocation processes, thereby blocking toxin action.
In the current work we characterized 4 PAs, each with a different set of mutations that show DN properties. In our initial study, the double mutant, K397D + D425K, proved to have slightly more potent DN activity than the D425K, the F427A, or the Δ2β2-2β3, which in turn were far more potent than the K397D (15). In the current study we used the double as the standard, and combined it with 2 other DN mutations of the original study. The triple contained the double plus the F427A mutation; and the quadruple contained the triple plus the Δ2β2-2β3. For the 4th mutant we chose the F427K single mutation to determine the effect of converting a strongly apolar side chain to one that is highly polar and positively charged.
Consistent with prior results, the 4 mutant PAs were not impaired in oligomerization, ligand binding, or by implication from the LFn-binding experiment shown in Figure 1, receptor binding. However all were profoundly defective in the pH-dependent functions such as pore formation as assayed by 86Rb release, the related property of conversion of the heptamer to an SDS-resistant conformation under acidic conditions, and translocation of LFn across the CHO-K1 plasma membrane. The F427K mutation was the weakest of the 4 mutants, causing significant levels of 86Rb release and formation of some SDS-resistant heptamer under acidic conditions.
Whereas introduction of the F427A mutation into the double caused no enhancement of its DN activity, the Δ2β2-2β3 mutation appeared to somewhat enhance the DN activity of the double in the low concentration range. This suggests that a single subunit of the double mutant may not be sufficient to inactivate completely an otherwise wild-type heptamer. If this is the case, a high percentage, but not all, of the heptamers containing a single double-mutant subunit may abort under acidic conditions. The DN activity of the F427K mutation was lower than that of the double or triple mutant at low concentrations, consistent with its activity levels found in the 86Rb release and SDS-resistant heptamer formation.
The finding that the DN activity of the double mutant is negated by introduction of a 3rd mutation (N682S) that blocks receptor binding is consistent with the notion that DN PA must bind to the PA receptor in order to co-oligomerize with wild-type PA. The finding that introduction into the double mutant of a 3rd mutation, D512K, that effectively blocks oligomerization did not affect DN activity would not necessarily have been predicted but can be readily explained. The D512K mutation would not be expected to block interaction of the double-mutant PA into wild-type oligomers as the opposite oligomerization interface of the mutant PA remains competent. Thus heptamers containing 6 wild-type PA subunits and a single K397D + K425K + D512K would be predicted to form. Only 1 of the 7 subunit:subunit interfaces in such a heteroheptamer would be perturbed, and apparently this structural perturbation is insufficient to affect translocation.
Although the quadruple mutant showed slightly enhanced DN activity relative to the double and triple mutants, the Δ2β2-2β3 destabilized the protein to a greater degree than the other mutations, as judged by intrinsic fluorescence of the proteins at various urea concentrations. This suggests that the quadruple mutant may also be less stable in vivo, which could compromise its activity as a DN inhibitor of toxin action or an immunogen. However the reductions in stability of the various mutants tested here may be of little or no physiological consequence given that we have seen no indications of instability in our other investigations of these proteins, and the double mutant, the F427A mutant, and the Δ2β2-2β3 mutant manifested immunogenicity at least equal to that of wild-type PA (15).
The DN forms of PA studied here and elsewhere represent a novel approach to both therapy and prophylaxis against anthrax. Not only do these mutant proteins have potent antitoxic activity, acting at substoichiometric levels with respect to wild-type PA, but also they retain the immunogenic properties of the parent molecule. Thus they may be of particular interest in post-exposure propylaxis, as well as therapy. The results reported here suggest that the double and triple mutants may have the best combination of DN activity and stability for these purposes. The various mutants will need to be tested in vivo to verify this prediction.
We thank Michael Mourez for help in this work and reading of the manuscript. This work was supported by NIH Grant AI-22021. RJC holds equity in PharmAthene Inc.